Document Detail

Phase I Study of Combination Chemotherapy Consisting of Paclitaxel, Cisplatin, and S-1 in Patients with Unresectable Gastric Cancer (KOGC-02).
MedLine Citation:
PMID:  23225443     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Triplet combination chemotherapy has the potential to improve the prognosis of patients with unresectable gastric cancer. We conducted a phase I trial of triplet combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 (PCS) for unresectable gastric cancer.
PATIENTS AND METHODS: Patients with metastatic or incurable disease were enrolled. S-1 was administered on days 1-14. Paclitaxel and cisplatin were infused on days 1 and 15. The starting doses of paclitaxel and cisplatin were 100 and 20 mg/m(2), respectively. Dose levels of paclitaxel and cisplatin were escalated as follows: 120 and 20 mg/m(2), respectively (level 2); 120 and 30 mg/m(2), respectively (level 3). End-points: Dose-limiting toxicities included grade 3 nausea, vomiting, and general fatigue, and grade 4 febrile neutropenia. The maximum tolerated dose and recommended dose were established at level 3 and level 2, respectively.
CONCLUSION: Although further clinical trials are recommended to more thoroughly evaluate safety and efficacy, PCS appears to be an excellent candidate for a standard treatment strategy for unresectable gastric cancer.
Tsunehiro Takahashi; Yoshiro Saikawa; Kazumasa Fukuda; Shinsuke Funakoshi; Hirofumi Kawakubo; Hiroya Takeuchi; Hiromasa Takaishi; Yuko Kitagawa
Related Documents :
1324643 - Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and spa...
7587053 - Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-...
16505623 - Radon concentrations in elementary schools in kuwait.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5401-6     Citation Subset:  IM    
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pemetrexed plus Carboplatin or Cisplatin as Neoadjuvant Treatment of Operable Malignant Pleural Meso...
Next Document:  Evaluation of 5-FU Plasma Concentration by 13C Breath Test in Patients Treated with Oral 5-FU Analog...